Mounjaro (tirzepatide) weightloss pens
| Variant | Price | unit |
|---|---|---|
| 1 pen | €999.00 | €999.00/pen |
Description
15mg Tirzepatide per pen (last 6 weeks for first time user!) (brand names Mounjaro and Zepbound) is a "dual agonist" medication, meaning it mimics two different hormones in your body: GLP-1 and GIP. Because it targets multiple pathways, its health benefits extend far beyond just lowering blood sugar. As of 2026, clinical trials and FDA approvals have identified several major health benefits: 1. Metabolic & Glycemic Control Type 2 Diabetes Management: It significantly lowers HbA1c (average blood sugar) by increasing insulin secretion and decreasing the liver's glucose production. Prevention of Diabetes: In clinical trials (SURMOUNT-1), tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity. Insulin Sensitivity: It improves how your cells respond to insulin, helping to reverse underlying metabolic dysfunction. 2. Significant Weight Reduction Substantial Fat Loss: It is one of the most effective weight-loss medications ever developed, with users in trials losing an average of 20% to 26% of their total body weight. Appetite Regulation: It acts on the brain’s satiety centers to reduce hunger and "food noise" (intrusive thoughts about eating). 3. Cardiovascular & Heart Health Heart Failure (HFpEF): Recent results from the SUMMIT trial show tirzepatide reduces the risk of "worsening heart failure events" by 38% in people with obesity and heart failure with preserved ejection fraction. Blood Pressure: It consistently reduces systolic blood pressure (by roughly 4–8 mmHg), likely due to a combination of weight loss and direct effects on blood vessels. Lipid Profile: It helps lower "bad" LDL cholesterol and significantly reduces triglycerides (often by 20% or more). 4. Sleep & Respiratory Health Obstructive Sleep Apnea (OSA): In 2024–2025, it gained recognition for significantly reducing the Apnea-Hypopnea Index (AHI). Some patients saw their sleep apnea symptoms resolve entirely as their weight decreased and airway inflammation went down. 5. Liver & Kidney Protection Fatty Liver (MASH/NASH): The SYNERGY-NASH trial showed that tirzepatide can resolve Metabolic Dysfunction-Associated Steatohepatitis (MASH) and even improve liver fibrosis (scarring). Kidney Function: It has shown "renoprotective" signals, meaning it may slow the progression of chronic kidney disease (CKD) by reducing inflammation and the amount of protein leaked into the urine (UACR). Summary of Benefits Diabetes: 94% reduction in progression from pre-diabetes. Weight: 20%+ total body weight loss. Heart: 38% reduction in worsening heart failure events. Sleep: Significant reduction in sleep apnea severity. Liver: Resolution of liver inflammation (MASH/NASH).